Skip to main content
SpringerLink
Log in

New antiretroviral drugs in clinical use

  • New Drugs Antibiotics
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

The advent of combination antiretroviral therapy for the treatment of human immunodeficiency virus (HIV) infection has dramatically changed the prognosis and quality of life of HIV-infected adults and children. To date, there are 21 antiretroviral agents available with only 11 agents being approved for the use in young children less than 6 years of age. The currently available antiretroviral agents belong to four different classes; nucleoside/nucleotide reverse transcriptase inhibitors (NRTI, NtRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), and a new class of fusion inhibitors (FI). It is recommended that the treatment regimen should be a combination of at least 3 drugs from different drug classes as this has been shown to slow disease progression, improve survival, and result in better virologic and immunologic responses. Treatment with antiretroviral agents is frequently complicated by the issues of adherence, tolerability, long term toxicity and drug resistance. Many efforts have been made to develop new antiretroviral agents with greater potency, higher tolerability profiles and better convenience. Some new agents are also effective against drug-resistant strains of HIV. Since 2001, there were 7 new antiretroviral agents and 2 fixed-dose multidrug formulations being approved for the treatment of HIV infection, most are approved only for use in adults. In this article, we will review new antiretroviral agents including emtricitabine, tenofovir disoproxil fumarate, atazanavir, fosamprenavir, tipranavir and enfuvirtide. Pediatric information on these drugs will be provided when available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Modrzejewski KA, Herman RA. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor.Ann Pharmacother 2004;38(6):1006–1014.

    Article  PubMed  CAS  Google Scholar 

  2. Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, Peck Aet al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.Antimicrob Agents Chemother 1992;36(11):2423–2431.

    PubMed  CAS  Google Scholar 

  3. Frampton JE, Perry CM. Emtricitabine: a review of its use in the management of HIV infection.Drugs 2005;65(10):1427–1448.

    Article  PubMed  CAS  Google Scholar 

  4. The Panel on Clinical Practices for Treatment of HIV Infection, The Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.http://AIDSinfo.nih.gov/ Accessed 1st September 2005.

  5. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JMet al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.Jama 2004;292(2):180–189.

    Article  PubMed  CAS  Google Scholar 

  6. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni Det al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.J Infect Dis 2000; 182(2):599–602.

    Article  PubMed  CAS  Google Scholar 

  7. Benson CA, van der Horst C, Lamarca A, Haas DW, McDonald CK, Steinhart CRet al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.Aids 2004;18(17):2269–2276.

    Article  PubMed  CAS  Google Scholar 

  8. Molina JM, Journot V, Morand-Joubert L, Yeni P, Rozenbaum W, Rancinan Cet al. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.J Infect Dis 2005;191(6): 830–839.

    Article  PubMed  CAS  Google Scholar 

  9. Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HAet al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.Antimicrob Agents Chemother 2002; 46(6):1734–1740.

    Article  PubMed  CAS  Google Scholar 

  10. Emtriva (Emtricitabine) package insert: CDER FDA Drug Approvals. Available from URL:http://www.fda.gov/cder/ foi/label/2003/21500_emtriva_lbl.pdf Accessed 1st September 2005.

  11. The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, The National Resource Center F-XBC, The Health Resources and Services Administration (HRSA), The National Institutes of Health (NIH). Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.http://aidsinfo.nih.gov/Accessed 1st September 2005.

  12. Wang LH, Wiznia AA, Rathore MH, Chittick GE, Bakshi SS, Emmanuel PJet al. Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children.Antimicrob Agents Chemother 2004;48(1):183–191.

    Article  PubMed  CAS  Google Scholar 

  13. Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor Aet al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.Aids 1999;13(16):2239–2250.

    Article  PubMed  CAS  Google Scholar 

  14. Truvada package insert. Available from URL:http:// www.gilead.com/pdf/truvada_pi.pdf Accessed 1st September 2005.

  15. Lyseng-Williamson KA, Reynolds NA, Plosker GL. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.Drugs 2005;65(3):413–432.

    Article  PubMed  CAS  Google Scholar 

  16. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA.Antimicrob Agents Chemother 1998;42(3):612–617.

    PubMed  CAS  Google Scholar 

  17. Mulato AS, Cherrington JM. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.Antiviral Res 1997;36(2):91–97.

    Article  PubMed  CAS  Google Scholar 

  18. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MDet al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.Jama 2004;292(2):191–201.

    Article  PubMed  CAS  Google Scholar 

  19. Squires K, Pozniak AL, Pierone G, Jr., Steinhart CR, Berger D, Bellos NCet al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.Ann Intern Med 2003;139(5 Pt 1):313–320.

    PubMed  CAS  Google Scholar 

  20. Negredo E, Molto J, Munoz-Moreno JA, Pedrol E, Ribera E, Viciana Pet al. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.Antivir Ther 2004;9(3):335–342.

    PubMed  CAS  Google Scholar 

  21. Viread package insert. Available from URL:http:// www.hivandhepatitis.com/hiv_and_aids/viread2005.pdf Accessed 1st September 2005.

  22. European Agency for the Evaluation of Medical Products. Viread (tenofovir disoproxil fumarate): Scientific discussion. Available from URL:http://www.emea.eu.int/humandocs/ PDFs/EPAR/viread/351001en6.pdf Accessed 1st September 2005.

  23. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D,et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.Clin Infect Dis 2003;36(8):1070–1073.

    Article  PubMed  Google Scholar 

  24. Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine.Clin Infect Dis 2003;36(8):1082–1085.

    Article  PubMed  Google Scholar 

  25. Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels Let al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/ hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.J Infect Dis 2002; 186(12):1844–1847.

    Article  PubMed  CAS  Google Scholar 

  26. Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner Aet al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.Antimicrob Agents Chemother 2004;48(5):1469–1487.

    Article  PubMed  Google Scholar 

  27. Reyataz package insert. Available from URL:http:// www.fda.gov/medwatch/SAFETY/2004/jul_PI/ Reyataz_PI.pdf Accessed 1st September 2005.

  28. Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WSet al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.Antimicrob Agents Chemother 2000;44(8):2093–2099.

    Article  PubMed  CAS  Google Scholar 

  29. Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher Tet al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviralnaive subjects: 48-week results.Aids 2003;17(18):2603–2614.

    Article  PubMed  CAS  Google Scholar 

  30. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JFet al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.J Acquir Immune Defic Syndr 2004;36(5): 1011–1019.

    Article  PubMed  CAS  Google Scholar 

  31. Nieto-Cisneros L, Zala C, Fessel EJ, Gonzalez-Garcia J, Cohen C, McGovern Ret al. Antiviral efficacy, metabolic changes and safety of atazanavir (ATV) versus lopinavir/ritonavir (LPV/ RTV) in combination with two nrtis in patients who have experienced virological failure with prior pi-containing regimen(s): 24-week results from BMS AI424-043. In2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; 2003; Paris, France:Antiviral Therapy 2003; 8(Suppl. 1):S212; 2003.

  32. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin Aet al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.Aids 2005;19(7):685–694.

    Article  PubMed  CAS  Google Scholar 

  33. Schnell T, Schmidt B, Moschik G, Thein C, Paatz C, Korn Ket al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.Aids 2003;17(8):1258–1261.

    Article  PubMed  Google Scholar 

  34. Musial BL, Chojnacki JK, Coleman CI. Atazanavir: a new protease inhibitor to treat HIV infection.Am J Health Syst Pharm 2004;61(13):1365–1374.

    PubMed  CAS  Google Scholar 

  35. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.J Acquir Immune Defic Syndr 2003; 32(1):18–29.

    PubMed  CAS  Google Scholar 

  36. Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes Det al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.Aids 2003;17(9):1339–1349.

    Article  PubMed  CAS  Google Scholar 

  37. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, Stoll M, Esser S, Voigt Eet al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.J Acquir Immune Defic Syndr 2005;39(2): 174–180.

    PubMed  Google Scholar 

  38. Haerter G, Manfras BJ, Mueller M, Kern P, Trein A. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir.Aids 2004;18(6):952–955.

    Article  PubMed  CAS  Google Scholar 

  39. Lexiva package insert. Available from URL:http:// www.hivandhepatitis.com//recent/protease/Lexiva%2010-20-03% 20Clean.pdf Accessed 1st September 2005.

  40. Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg Set al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.J Clin Pharmacol 2002;42(8):887–898.

    Article  PubMed  CAS  Google Scholar 

  41. Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RBet al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.Antimicrob Agents Chemother 2004; 48(1):116–123.

    Article  PubMed  CAS  Google Scholar 

  42. Gathe JC, Jr., Ive P, Wood R, Schurmann D, Bellos NC, DeJesus Eet al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.Aids 2004;18(11):1529–1537.

    Article  PubMed  CAS  Google Scholar 

  43. Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GEet al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.J Acquir Immune Defic Syndr 2004;35(1):22–32.

    Article  PubMed  CAS  Google Scholar 

  44. Elston RC, Yates P, Tisdale M, Richards N, Whites S, DeJesus E. GW433908 (908)/ritronavir (r): 48 week results in PI-experienced subjects: A retrospective analysis of virological response based on baseline genotype and phenotype. xv International AIDS Conference, July 11–16, 2004; Bangkok, Thailand. http://www.iasociety.org/ejias/ print.asp?abstract_id=2168938 Accessed 1st September 2005.

  45. Roche Laboratories Inc. and Trimeris Inc. Fuzeon package insert. Available from URL:http://www.fuzeon.com/ common/fpi.pdf Accessed 1st September 2005.

  46. Jamjian MC, McNicholl IR. Enfuvirtide: first fusion inhibitor for treatment of HIV infection.Am J Health Syst Pharm 2004; 61(12):1242–1247.

    PubMed  CAS  Google Scholar 

  47. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier Bet al. Enfuvirtide, an HIV-1 fusion inhibitor, for drugresistant HIV infection in North and South America.N Engl J Med 2003;348(22):2175–2185.

    Article  PubMed  CAS  Google Scholar 

  48. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson Met al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.N Engl J Med 2003; 348(22):2186–2195.

    Article  PubMed  CAS  Google Scholar 

  49. Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora Pet al. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.Pediatr Infect Dis J 2004;23(8):713–718.

    Article  PubMed  Google Scholar 

  50. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron Met al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.Proc Natl Acad Sci USA 2002;99(25):16249–16254.

    Article  PubMed  CAS  Google Scholar 

  51. Carmona R, Perez-Alvarez L, Munoz M, Casado G, Delgado E, Sierra Met al. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients.J Clin Virol 2005;32(3):248–253.

    Article  PubMed  CAS  Google Scholar 

  52. Poveda E, Rodes B, Labernardiere JL, Benito JM, Toro C, Gonzalez-Lahoz Jet al. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.J Med Virol 2004;74(1):21–28.

    Article  PubMed  CAS  Google Scholar 

  53. Moyle G. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART.J Antimicrob Chemother 2003;51(2): 213–217.

    Article  PubMed  CAS  Google Scholar 

  54. Miller MD, Hazuda DJ. HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications.Drug Resist Updat 2004;7(2):89–95.

    Article  PubMed  CAS  Google Scholar 

  55. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RCet al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.AIDS Res Hum Retroviruses 2002;18(10):685–693.

    Article  PubMed  CAS  Google Scholar 

  56. Ball RA, Kinchelow T. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.J Am Acad Dermatol 2003;49(5): 826–831.

    Article  PubMed  Google Scholar 

  57. Plosker GL, Figgitt DP. Tipranavir.Drugs 2003;63(15):1611–1618.

    Article  PubMed  CAS  Google Scholar 

  58. Larder BA, Hertogs K, Bloor S, van den Eynde CH, DeCian W, Wang Yet al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.Aids 2000;14(13):1943–1948.

    Article  PubMed  CAS  Google Scholar 

  59. Aptivus package insert.http://www.fda.gov/cder/foi/label/ 2005/021814lbl.pdf Accessed 1st September 2005.

  60. Chong KT, Pagano PJ. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and-resistant clinical isolates.Antimicrob Agents Chemother 1997;41(11):2367–2373.

    PubMed  CAS  Google Scholar 

  61. Mehandru S, Markowitz M. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.Expert Opin Investig Drugs 2003;12(11):1821–1828.

    Article  PubMed  CAS  Google Scholar 

  62. Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta Cet al. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.Antimicrob Agents Chemother 2000;44(5):1328–1332.

    Article  PubMed  CAS  Google Scholar 

  63. Cooper D, Ć H, Cahn P, Lazzarin A, Walmsley S, Arasteh K,et al. 24-week RESIST study analyses: the efficacy of tipranavir/ritronavir (TPV/r) is superior to lopinavir/ retronavir (LPV/r), and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR) [Abstract no. 560]. 12th Conference on Retroviruses and Opportunistic Infections, Feb 22–25, 2005; Boston. http://medadvocates.org/resources/ conferences/croi/12_croi/tipranavir_%20RESIST.pdf Accessed 1st September 2005.

  64. Hicks C and the RESIST-1 study team. RESIST-1: A phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritronavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data [Abstract no.3726]. 44th ICAAC, Oct 31–Nov 2, 2004; Washington, DC. http://medadvocates.org/resources/ conferences/icaac/44_icaac/tip_resist.htm Accessed 1st September 2005.

Download references

Author information

Authors and Affiliations

  1. Carman and Ann Adams Department of Pediatrics, Wayne State University, School of Medicine, Detroit, Michigan, USA

    Pimpanada Chearskul, Chokechai Rongkavilit, Hossam Al-Tatari & Basim Asmar

  2. Division of Infectious Diseases, Children's Hospital of Michigan, 3901 Beaubien Blvd, 48201, Detroit, Michigan

    Pimpanada Chearskul, Chokechai Rongkavilit, Hossam Al-Tatari & Basim Asmar

Authors
  1. Pimpanada Chearskul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chokechai Rongkavilit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hossam Al-Tatari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Basim Asmar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chokechai Rongkavilit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chearskul, P., Rongkavilit, C., Al-Tatari, H. et al. New antiretroviral drugs in clinical use. Indian J Pediatr 73, 335–341 (2006). https://doi.org/10.1007/BF02825828

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02825828

Key words

Search

Navigation